| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pathology and Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY 10016;
Department of Anatomic Pathology, University of Torino, Torino, Italy; Divisions of
Pediatric Hematology/Oncology and
§
Hematology/Oncology, Department of Medicine, New York University Medical Center, New York, NY 10016; and
¶
Department of Microbiology, Miami University, Miami, FL 33101
The biological function of CD30 in the thymus has been only
partially elucidated, although recent data indicate that it may be
involved in negative selection. Because CD30 is expressed only by a
small subpopulation of medullary thymocytes, we generated transgenic
(Tg) mice overexpressing CD30 in T lymphocytes to further address its
role in T cell development. CD30 Tg mice have normal thymic size with a
normal number and subset distribution of thymocytes. In vitro, in the
absence of CD30 ligation, thymocytes of CD30 Tg mice have normal
survival and responses to apoptotic stimuli such as radiation,
dexamethasone, and Fas. However, in contrast to controls, CD30 Tg
thymocytes are induced to undergo programmed cell death (PCD) upon
cross-linking of CD30, and the simultaneous engagement of TCR and CD30
results in a synergistic increase in thymic PCD. CD30-mediated PCD
requires caspase 1 and caspase 3, is not associated with the activation
of NF-
B or c-Jun, but is totally prevented by Bcl-2. Furthermore,
CD30 overexpression enhances the deletion of
CD4+/CD8+ thymocytes induced by staphylococcal
enterotoxin B superantigen and specific peptide. These findings suggest
that CD30 may act as a costimulatory molecule in thymic negative
selection.
This article has been cited by other articles:
|
|
 |
|
  C. Menzel, T. Schirrmann, Z. Konthur, T. Jostock, and S. Dubel Human antibody RNase fusion protein targeting CD30+ lymphomas Blood, April 1, 2008; 111(7): 3830 - 3837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cretney, A. P. Uldrich, F. W. McNab, D. I. Godfrey, and M. J. Smyth No requirement for TRAIL in intrathymic negative selection Int. Immunol., February 1, 2008; 20(2): 267 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Wright, J. M. Rumble, and C. S. Duckett CD30 Activates Both the Canonical and Alternative NF-{kappa}B Pathways in Anaplastic Large Cell Lymphoma Cells J. Biol. Chem., April 6, 2007; 282(14): 10252 - 10262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zeiser, V. H. Nguyen, J.-Z. Hou, A. Beilhack, E. Zambricki, M. Buess, C. H. Contag, and R. S. Negrin Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease Blood, March 1, 2007; 109(5): 2225 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schnell, M. Dietlein, J. O. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody J. Clin. Oncol., July 20, 2005; 23(21): 4669 - 4678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Fisher, M. Nagarkatti, and P. S. Nagarkatti 2,3,7,8-Tetrachlorodibenzo-p-dioxin Enhances Negative Selection of T Cells in the Thymus but Allows Autoreactive T Cells to Escape Deletion and Migrate to the Periphery Mol. Pharmacol., January 1, 2005; 67(1): 327 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Blazar, R. B. Levy, T. W. Mak, A. Panoskaltsis-Mortari, H. Muta, M. Jones, M. Roskos, J. S. Serody, H. Yagita, E. R. Podack, et al. CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease J. Immunol., September 1, 2004; 173(5): 2933 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Berro, G. A. Perry, and D. K. Agrawal Increased Expression and Activation of CD30 Induce Apoptosis in Human Blood Eosinophils J. Immunol., August 1, 2004; 173(3): 2174 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Su, H.-H. Chiu, C.-C. Chang, J.-C. Chen, and S.-M. Hsu CD30 Is Involved in Inhibition of T-Cell Proliferation by Hodgkin's Reed-Sternberg Cells1 Cancer Res., March 15, 2004; 64(6): 2148 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Fisher, M. Nagarkatti, and P. S. Nagarkatti Combined Screening of Thymocytes Using Apoptosis-Specific cDNA Array and Promoter Analysis Yields Novel Gene Targets Mediating TCDD-Induced Toxicity Toxicol. Sci., March 1, 2004; 78(1): 116 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Matsumoto, M. Terakawa, K. Miura, S. Fukuda, T. Nakajima, and H. Saito Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment In Vitro J. Immunol., February 15, 2004; 172(4): 2186 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Toennies, J. M. Green, and R. H. Arch Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms J. Leukoc. Biol., February 1, 2004; 75(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma Blood, November 15, 2003; 102(10): 3737 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Willers, R. Dummer, W. Kempf, T. Kundig, G. Burg, and M. E. Kadin Proliferation of CD30+ T-Helper 2 Lymphoma Cells Can Be Inhibited by CD30 Receptor Cross-Linking with Recombinant CD30 Ligand Clin. Cancer Res., July 1, 2003; 9(7): 2744 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood, March 1, 2003; 101(5): 1919 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Piva, J. Liu, R. Chiarle, A. Podda, M. Pagano, and G. Inghirami In Vivo Interference with Skp1 Function Leads to Genetic Instability and Neoplastic Transformation Mol. Cell. Biol., December 1, 2002; 22(23): 8375 - 8387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saraiva, P. Smith, P. G. Fallon, and A. Alcami Inhibition of Type 1 Cytokine-mediated Inflammation by a Soluble CD30 Homologue Encoded by Ectromelia (Mousepox) Virus J. Exp. Med., September 16, 2002; 196(6): 829 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Harlin, E. Podack, M. Boothby, and M.-L. Alegre TCR-Independent CD30 Signaling Selectively Induces IL-13 Production Via a TNF Receptor-Associated Factor/p38 Mitogen-Activated Protein Kinase-Dependent Mechanism J. Immunol., September 1, 2002; 169(5): 2451 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Chan, C. D. Hopke, S. M. Krams, and O. M. Martinez CD30 Expression Identifies the Predominant Proliferating T Lymphocyte Population in Human Alloimmune Responses J. Immunol., August 15, 2002; 169(4): 1784 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Wahl, K. Klussman, J. D. Thompson, J. H. Chen, L. V. Francisco, G. Risdon, D. F. Chace, C. B. Siegall, and J. A. Francisco The Anti-CD30 Monoclonal Antibody SGN-30 Promotes Growth Arrest and DNA Fragmentation in Vitro and Affects Antitumor Activity in Models of Hodgkin's Disease Cancer Res., July 1, 2002; 62(13): 3736 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Chandel, P. T. Schumacker, and R. H. Arch Reactive Oxygen Species Are Downstream Products of TRAF-mediated Signal Transduction J. Biol. Chem., November 9, 2001; 276(46): 42728 - 42736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, T. Chun, J. C. Lo, Q. Wu, Y. Wang, A. Foster, K. Roca, M. Chen, K. Tamada, L. Chen, et al. The Critical Role of LIGHT, a TNF Family Member, in T Cell Development J. Immunol., November 1, 2001; 167(9): 5099 - 5105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Y. Wang, A. Thern, A. Denzel, J. Kitson, S. N. Farrow, and M. J. Owen DR3 Regulates Negative Selection during Thymocyte Development Mol. Cell. Biol., May 15, 2001; 21(10): 3451 - 3461. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Latres, R. Chiarle, B. A. Schulman, N. P. Pavletich, A. Pellicer, G. Inghirami, and M. Pagano Role of the F-box protein Skp2 in lymphomagenesis PNAS, February 15, 2001; (2001) 41475098. [Abstract] [Full Text]
|
|
|
|
|
|
A. L. DeYoung, O. Duramad, and A. Winoto The TNF Receptor Family Member CD30 Is Not Essential for Negative Selection J. Immunol., December 1, 2000; 165(11): 6170 - 6173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Muta, L. H. Boise, L. Fang, and E. R. Podack CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis J. Immunol., November 1, 2000; 165(9): 5105 - 5111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Annunziato, P. Romagnani, L. Cosmi, C. Beltrame, B. H. Steiner, E. Lazzeri, C. J. Raport, G. Galli, R. Manetti, C. Mavilia, et al. Macrophage-Derived Chemokine and EBI1-Ligand Chemokine Attract Human Thymocytes in Different Stage of Development and Are Produced by Distinct Subsets of Medullary Epithelial Cells: Possible Implications for Negative Selection J. Immunol., July 1, 2000; 165(1): 238 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Kadin Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease Am. J. Pathol., May 1, 2000; 156(5): 1479 - 1484. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Croager, A. M. Gout, and L. J. Abraham Involvement of Sp1 and Microsatellite Repressor Sequences in the Transcriptional Control of the Human CD30 Gene Am. J. Pathol., May 1, 2000; 156(5): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Zhu, D. DeRyckere, F. X. Li, Y. Y. Wan, and J. DeGregori A Role for E2F1 in the Induction of ARF, p53, and Apoptosis during Thymic Negative Selection Cell Growth Differ., December 1, 1999; 10(12): 829 - 838. [Abstract] [Full Text]
|
|
|
|
|
|
E. Latres, R. Chiarle, B. A. Schulman, N. P. Pavletich, A. Pellicer, G. Inghirami, and M. Pagano Role of the F-box protein Skp2 in lymphomagenesis PNAS, February 27, 2001; 98(5): 2515 - 2520. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
